Prof. Juliane Walz receives prestigous award from Roche

🏆A great recognition and a big surprise for our spokesperson Prof. Dr. med. Juliane S. Walz! Together with Jens Bauer, she was awarded the "Best Overall Award" during the "überDACHt – Roche Science & Innovation Summit" in Basel for their clinical trial "FusionVac_22".

💉This phase I study will assess the safety and efficacy of a peptide vaccine (Fusion-VAC-XS15) against FLC’s driver protein in a different clinical context than has been examined to date. The goal is to significantly delay or entirely prevent the return of the cancer.

💡If successful, this new study could deliver a new treatment to prevent recurrence of FLC. This would address a major unmet need of the patient community, especially for individuals who achieve complete remission status, yet still carry a population of FLC cancer cells that could lead to relapse of their disease.

🇨🇭The award was presented to her in the presence of Katharina M. Gasser, General Manager of Roche Pharma Switzerland, Doris Schwindt, Head Pharma Operations at Roche Pharma Ltd and Alexander Muelhaupt, General Manager at Roche New Zealand.

🥳Congratulations!

Credits: Roche Pharma